NCT00483600

Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction

Studies of Fondaparinux in Patients With Renal Dysfunction: PK Study of Fondaparinux in Outpatients With Renal Dysfunction

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Duke University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To determine the appropriate dose and safety of a preventative dose of fondaparinux, an anticoagulant medication (blood thinner) in patients with kidney disease.

Detailed description

This study will evaluate the PK of fondaparinux in patients who have renal insufficiency. Fondaparinux is cleared from the body mainly by the kidneys. Therefore in patients with kidney diseases, full doses of fondaparinux could cause bleeding problems. The correct dose of fondaparinux that should be used in patients with kidney disease is not known. The purpose of this research is to determine the PK and safety of a preventative dose (2.5mg subcutaneously every other day) of fondaparinux for patients with kidney disease.

Conditions

• Kidney Diseases

Interventions

Type	Name	Description
DRUG	fondaparinux	injections of 2.5mg every other day for 4 weeks

Timeline

• Start date: 2007-08-01
• Completion: 2008-08-01
• First posted: 2007-06-07
• Last updated: 2014-07-29

Locations

1 site across 1 country: United States